{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:48:20Z","timestamp":1789469300490,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31471286"],"award-info":[{"award-number":["31471286"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010903","name":"Key Programme","doi-asserted-by":"publisher","award":["81772693"],"award-info":[{"award-number":["81772693"]}],"id":[{"id":"10.13039\/501100010903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"crossref","award":["2019YFS0108"],"award-info":[{"award-number":["2019YFS0108"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00262-021-02856-0","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T14:06:33Z","timestamp":1612447593000},"page":"2453-2465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma"],"prefix":"10.1007","volume":"70","author":[{"given":"Jianhan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-9294","authenticated-orcid":false,"given":"Liangxue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"2856_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1001\/jamaoncol.2017.2989","volume":"11","author":"JM Pagel","year":"2017","unstructured":"Pagel JM, West HJ (2017) Chimeric antigen receptor (CAR) T-cell therapy. JAMA Oncol 11:1595","journal-title":"JAMA Oncol"},{"key":"2856_CR2","first-page":"5","volume":"1","author":"J Calmes-Miller","year":"2018","unstructured":"Calmes-Miller J (2018) FDA approves second CAR T-cell therapy. Cancer Discov 1:5\u20136","journal-title":"Cancer Discov"},{"key":"2856_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","volume":"1","author":"J Li","year":"2018","unstructured":"Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q (2018) Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol 1:22","journal-title":"J Hematol Oncol"},{"key":"2856_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"1","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 1:17\u201335","journal-title":"Immunity"},{"key":"2856_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"5","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS (2019) Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 5:471\u2013482","journal-title":"Cancer Cell"},{"key":"2856_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"4","author":"X Ma","year":"2020","unstructured":"Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, Porterfield Kren N, Michaud D, Ahn S, Vincent B et al (2020) Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol 4:448\u2013459","journal-title":"Nat Biotechnol"},{"key":"2856_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"9","author":"K Harrington","year":"2019","unstructured":"Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC (2019) Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov 9:689\u2013706","journal-title":"Nat Rev Drug Discov"},{"key":"2856_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","volume":"1","author":"O Hemminki","year":"2020","unstructured":"Hemminki O, Dos Santos JM, Hemminki A (2020) Oncolytic viruses for cancer immunotherapy. Journal of Hematol Oncol 1:84","journal-title":"Journal of Hematol Oncol"},{"key":"2856_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","volume":"7","author":"K Twumasi-Boateng","year":"2018","unstructured":"Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH (2018) Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer 7:419\u2013432","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2856_CR10","doi-asserted-by":"publisher","first-page":"e000710","DOI":"10.1136\/jitc-2020-000710","volume":"8","author":"Y Ge","year":"2020","unstructured":"Ge Y, Wang H, Ren J, Liu W, Chen L, Chen H, Ye J, Dai E, Ma C, Ju S et al (2020) Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. J Immunother Cancer 8(1):e000710","journal-title":"J Immunother Cancer"},{"key":"2856_CR11","doi-asserted-by":"publisher","unstructured":"Nakao S, Arai Y, Tasaki M, Yamashita M, Murakami R, Kawase T, Amino N, Nakatake M, Kurosaki H, Mori M et al (2020) Intratumoral expression of IL7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med.\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aax7992","DOI":"10.1126\/scitranslmed.aax7992"},{"key":"2856_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/1078-0432.CCR-13-1016","volume":"1","author":"SK Perna","year":"2014","unstructured":"Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G (2014) Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 1:131\u2013139","journal-title":"Clin Cancer Res"},{"key":"2856_CR13","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"11","author":"T Shum","year":"2017","unstructured":"Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R et al (2017) Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 11:1238\u20131247","journal-title":"Cancer Discov"},{"key":"2856_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"4","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K (2018) IL7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 4:346\u2013351","journal-title":"Nat Biotechnol"},{"key":"2856_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","volume":"14","author":"X Tang","year":"2019","unstructured":"Tang X, Zhao S, Zhang Y, Wang Y, Zhang Z, Yang M, Zhu Y, Zhang G, Guo G, Tong A et al (2019) B7\u2013H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncol 14:279\u2013287","journal-title":"Mol Ther Oncol"},{"key":"2856_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1476-4598-9-10","volume":"9","author":"X Li","year":"2010","unstructured":"Li X, Liu Y, Wen Z, Li C, Lu H, Tian M, Jin K, Sun L, Gao P, Yang E et al (2010) Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer 9:10","journal-title":"Mol Cancer"},{"key":"2856_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.0105-2896.2006.00382.x","volume":"211","author":"MF Mescher","year":"2006","unstructured":"Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z (2006) Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 211:81\u201392","journal-title":"Immunol Rev"},{"key":"2856_CR18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","volume":"10","author":"J Zhou","year":"2019","unstructured":"Zhou J, Jin L, Wang F, Zhang Y, Liu B, Zhao T (2019) Chimeric antigen receptor T (CAR-T) cells expanded with IL7\/IL-15 mediate superior antitumor effects. Protein Cell 10:764\u2013769","journal-title":"Protein Cell"},{"key":"2856_CR19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrclinonc.2018.34","volume":"5","author":"P Sidaway","year":"2018","unstructured":"Sidaway P (2018) CNS cancer: Oncolytic adenovirus effective in patients with glioblastoma. Nat Rev Clin Oncol 5:266","journal-title":"Nat Rev Clin Oncol"},{"key":"2856_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/sj.cr.7310025","volume":"2","author":"C Qian","year":"2006","unstructured":"Qian C, Liu XY, Prieto J (2006) Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res 2:182\u2013188","journal-title":"Cell Res"},{"key":"2856_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","volume":"5","author":"A Wing","year":"2018","unstructured":"Wing A, Fajardo CA, Posey AD, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S (2018) Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Cancer Immunol Res 5:605\u2013616","journal-title":"Cancer Immunol Res"},{"key":"2856_CR22","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"8","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C et al (2019) CAR T cells targeting B7\u2013H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res 8:2560\u20132574","journal-title":"Clin Cancer Res"},{"key":"2856_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","volume":"6","author":"K Flem-Karlsen","year":"2018","unstructured":"Flem-Karlsen K, Fodstad \u00d8, Tan M, Nunes-Xavier CE (2018) B7\u2013H3 in cancer\u2014beyond immune regulation. Trends in Cancer 6:401\u2013404","journal-title":"Trends in Cancer"},{"key":"2856_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","volume":"17","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Jiang C, Liu Z, Yang M, Tang X, Wang Y, Zheng M, Huang J, Zhong K, Zhao S et al (2020) B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors. Mol Ther Oncol 17:180\u2013189","journal-title":"Mol Ther Oncol"},{"key":"2856_CR25","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"26","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. New Engl J Med 26:2561\u20132569","journal-title":"New Engl J Med"},{"key":"2856_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"8","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A et al (2017) HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol 8:1094\u20131101","journal-title":"JAMA Oncol"},{"key":"2856_CR27","doi-asserted-by":"publisher","first-page":"e1412902","DOI":"10.1080\/2162402X.2017.1412902","volume":"5","author":"V Cervera-Carrascon","year":"2018","unstructured":"Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, T\u00e4htinen S, Karell P, Sorsa S, Kanerva A, Hemminki A (2018) TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology 5:e1412902","journal-title":"Oncoimmunology"},{"key":"2856_CR28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","volume":"1","author":"P Wang","year":"2017","unstructured":"Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z, Liu H, Jiang G et al (2017) Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun 1:1395","journal-title":"Nat Commun"},{"key":"2856_CR29","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","volume":"8","author":"CA Fajardo","year":"2017","unstructured":"Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, Alemany R (2017) Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Can Res 8:2052\u20132063","journal-title":"Can Res"},{"key":"2856_CR30","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","volume":"5","author":"CE Porter","year":"2020","unstructured":"Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, Sikora A, Gottschalk S, Ittman MM, Brenner MK et al (2020) Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol Ther 5:1251\u20131262","journal-title":"Mol Ther"},{"issue":"50","key":"2856_CR31","doi-asserted-by":"publisher","first-page":"30018","DOI":"10.1074\/jbc.M115.679852","volume":"290","author":"M Ahmed","year":"2015","unstructured":"Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo HF, Larson SM, Cheung NK (2015) Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7\u2013H3. J Biol Chem 290(50):30018\u201330029.\u00a0https:\/\/doi.org\/10.1074\/jbc.M115.679852","journal-title":"J Biol Chem"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02856-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02856-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02856-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T08:06:40Z","timestamp":1628755600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02856-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2856"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02856-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-61545\/v1","asserted-by":"object"}]},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"13 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments followed a protocol approved by the Institutional Animal Care and Use Committee of Sichuan University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}]}}